Aurobindo Pharma Subsidiary Completes A1 Biochem Acquisition

Date: October 2, 2026

Apitoria Pharma Private Limited, a wholly owned subsidiary of Aurobindo Pharma, has completed the acquisition of the Contract Research Services business of A1 Biochem Group.
The acquisition was completed post fulfillment of conditions prescribed under the definitive agreements.
Apitoria now holds 80% ownership in A1 Biochem Labs (India) Private Limited (A1 Labs India).
Dr. Rajendra Gadikota (former promoter of A1 Biochem Group) holds the remaining 20% ownership in A1 Labs India.
A1 Labs India, through its wholly owned subsidiary A1 Biochem USA Inc, USA, has acquired 100% membership interest of A1 Biochem Labs LLC, USA (step-down subsidiary of A1 Labs India) which operates in USA.
The acquisition provides Apitoria access to an existing CRO platform with 50+ client base and experience of completing 800+ projects in India and USA.
This acquisition complements Apitoria's manufacturing capabilities to create an integrated CRDMO platform.
The transaction expands the portfolio of offerings to customers and enables longer life cycle engagement with customers.